kabutan

StemRIM rises for fourth straight session after completing patient enrollment in Phase 1/2 trial

Thu Apr 16, 2026 9:55 am JST Catalyst

Shares of StemRIM <4599> gained for a fourth consecutive session after the company announced the completed patient enrollment in a Phase 1/2 clinical trial for its out-licensed regenerative medicine candidate. The investigator-initiated trial of ledasemtide (HMGB1 peptide), licensed to Shionogi & Co Ltd <4507>, targets patients with ischemic cardiomyopathy. StemRIM noted the milestone will not impact its earnings guidance for the fiscal year ending July 2026.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Related Articles